ClinicalTrials.gg
Active, not recruitingNCT03732820Updated Aug 18, 2026Results posted

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

A Phase 3 interventional study of olaparib and abiraterone acetate in Metastatic Castration-resistant Prostate Cancer, sponsored by AstraZeneca. Active, not recruiting at 132 sites in 17 countries. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
895
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing olaparib in Prostatic Neoplasms — 2 open to participants now, 11 under way, 2 of them phase 3. olaparib · Prostatic Neoplasms.

Enrollment
2nd of 25
895 · median 43
Started
2018
with 3 others
Phase 3
4 of 25
none open now
Primary completion
2021-07
later than 0 of 10 live
Registered
11th of 25
by date
Lead sponsor
5 of 25
AstraZeneca

Among the 25 studies testing olaparib in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is one of 4 that started in 2018, is one of 4 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 11th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 25 studies testing olaparib in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 99 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing olaparib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

Read the detailed description

PROpel is a phase III study evaluating the efficacy, safety, and tolerability of olaparib versus placebo when given in addition to abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting).

Approximately 720 patients globally were planned to be randomized in PROpel in a 1:1 ratio to treatment with either olaparib and abiraterone or placebo and abiraterone. Enrolment had completed with a total of 796 patients randomised. Following the completion of global enrolment, the China cohort will randomise approximately 108 additional patients at sites in China, also in a 1:1 ratio.

Patients will receive oral treatment with olaparib 300 mg twice daily + abiraterone 1000 mg once daily or placebo twice daily + abiraterone 1000 mg once daily. Patients in both treatment groups will also receive either prednisone or prednisolone 5 mg twice daily.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • metastatic castration-resistant prostate cancer (mCRPC)
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form and in the study protocol.
  2. Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses.
  3. For inclusion in i) the optional exploratory genetic research and ii) the optional biomarker research, patients must fulfill the following criteria:

    • Provision of informed consent for genetic research prior to collection of sample.
    • Provision of informed consent for biomarker research prior to collection of sample.

    If a patient declines to participate in the optional exploratory genetic research or the optional biomarker research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study.

  4. Patients must be ≥18 years of age (or ≥19 years of age in South Korea) at the time of signing the informed consent form. For patients enrolled in Japan who are \<20 years of age, written informed consent should be obtained from the patient and from his legally acceptable representative.
  5. or cytologically confirmed prostate adenocarcinoma.
  6. status defined as at least 1 documented metastatic lesion on either a bone scan or a computed tomography(CT)/ magnetic resonance imaging (MRI) scan.
  7. metastatic castration-resistant prostate cancer (mCRPC).
  8. Ongoing androgen deprivation with gonadotropin-releasing hormone analogue or bilateral orchiectomy, with serum testosterone \<50 nanograms per decilitre (ng/dL) (\<2.0 nanomoles per litre (nmol/L)) within 28 days before randomisation. Patients receiving androgen deprivation therapy (ADT) at study entry should continue to do so throughout the study.
  9. Candidate for abiraterone therapy with documented evidence of progressive disease.
  10. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment.
  11. (ECOG) performance status 0-1, with no deterioration over the previous 2 weeks.
  12. The participant has, in the opinion of the investigator, a of at least 6 months.
  13. Prior to randomisation, sites must confirm availability of either an archival formalin fixed, paraffin embedded (FFPE) tumour tissue sample, or a new taken during the screening window, which meets the minimum pathology and sample requirements in order to enable homologous recombination repair (HRR) status subgroup analysis of the primary endpoint radiographic progression-free survival (rPFS). If there is not written confirmation of the availability of tumour tissue prior to randomisation, the patient is not eligible for the study.
  14. Male patients must use a condom during treatment and for 3 months after the last dose of olaparib+abiraterone when having sexual intercourse with a pregnant woman or with a woman of . Female partners of male patients should also use a highly effective form of if they are of childbearing potential.

Exclusion criteria

Exclusion Criteria:

  1. Has a known additional that has had progression or has required active treatment in the last 5 years.
  2. Patients with myelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML) or with features suggestive of yelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML).
  3. cardiovascular disease Association Class II-IV heart failure or cardiac measurement of \<50% during screening as assessed by echocardiography or multigated acquisition scan.
  4. Planned or scheduled cardiac surgery or percutaneous coronary intervention procedure.
  5. Prior revascularisation procedure (significant coronary, carotid, or peripheral artery stenosis).
  6. Uncontrolled hypertension (systolic blood pressure (BP) ≥160 millimeters of mercury (mmHg) or diastolic blood pressure (BP) ≥95 millimeters of mercury (mmHg)).
  7. History of uncontrolled pituitary or adrenal dysfunction.
  8. Active infection or other medical condition that would make prednisone/prednisolone use .
  9. Any chronic medical condition requiring a systemic dose of >10 milligrams (mg) prednisone/prednisolone per day.
  10. Patients who are considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
  11. Persistent toxicities ( [CTCAEs] grade >2) caused by previous cancer therapy, excluding alopecia.
  12. Patients with . A scan to confirm the absence of brain metastases is not required.
  13. Patients with spinal cord compression are excluded unless they are considered to have received definitive treatment for this and have evidence of clinically stable disease for 4 weeks.
  14. Patients who are unevaluable for both bone and soft tissue progression
  15. Patients who are unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  16. patients
  17. Patients with known active hepatitis infection (ie, or C).
  18. Any previous treatment with Polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerase (PARP) inhibitor, including olaparib.
  19. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment. Patients who receive palliative radiotherapy need to stop radiotherapy 1 week before randomisation.
  20. Any previous exposure to a Cytochrome P450 (CYP) 17 (17α-hydroxylase/C17,20-lyase) inhibitor (eg, abiraterone, orteronel).
  21. Concomitant use of known strong Cytochrome P450 (CYP) 3A inhibitors (eg, itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate inhibitors (eg, ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required prior to starting study treatment is 2 weeks.
  22. Concomitant use of known strong Cytochrome P450 (CYP) 3A inducers (eg, phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine or St John's wort) or moderate Cytochrome P450 (CYP) 3A inducers (eg, bosentan, efavirenz or modafinil). The required period prior to starting study treatment is 5 weeks for phenobarbital and enzalutamide and 3 weeks for other agents.
  23. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
  24. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
  25. Participation in another clinical study with an product or investigational medical devices within 1 month of randomisation.
  26. History of to olaparib or abiraterone, any of the of olaparib or abiraterone, or drugs with a similar chemical structure or class to olaparib or abiraterone.
  27. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca and Merck staff and/or staff at the study site).
  28. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
  29. Previous randomisation in the present study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
895 participants (actual)

Study arms

  • Experimental
    olaparib plus abiraterone

    Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study. Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily.

    Drug: olaparib · Drug: abiraterone acetate

  • Placebo comparator
    placebo plus abiraterone

    Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study. Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily.

    Drug: abiraterone acetate

Interventions

  • 300 mg (2 x 150 milligrams (mg) tablets) twice daily

    Also known as: Lynparza

  • 1000 milligrams (mg) once daily

    Also known as: Zytiga

06

What researchers measure

Primary outcomes

  1. Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment

    An rPFS event is defined as progression determined by Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\] and/or Prostate Cancer Working Group 3 \[PCWG-3\] or death (by any cause in the absence of progression), regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy prior to progression. Per RECIST v1.1, progression is defined as the sum of TLs has a 20% and absolute ≥ 5mm increase from nadir, and/or unequivocal progression in any non target lesions, and/or any new lesion identified. Per PCWG3, progression on a bone scan is defined as 2 or more new lesions observed from the first visit after baseline compared to baseline, or from all other visits compared to first visit after baseline. A confirmatory scan is required.

    Time frame: Assessed from date of randomisation to data cut off (DCO1): 30Jul2021 (Approx. 2 years 9 months)

Secondary outcomes

  1. Number of Participants With Overall Survival (OS) Event

    An OS event is defined as death by any cause, regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy.

    Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months). DCO3 is the final data cut-off for the OS analysis and therefore no further updates will be made.

  2. Number of Participants With Time to First Subsequent Anticancer Therapy or Death (TFST) Event

    A TFST (excluding radiotherapy) event is defined as the start of the first subsequent anticancer therapy after discontinuation of randomised treatment or death from any cause.

    Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)

  3. Number of Participants With Time to Pain Progression (TTPP) Event

    A TTPP event is defined as pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 (range 0-10, a higher score indicates worse pain) and opiate analgesic use (Analgesic quantification algorithm \[AQA\] score, range 0-7, a higher score indicates increased opioid use). For patients who are asymptomatic at baseline (average worst pain score of 0 and not taking opioids): A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits or initiation of opioid use; For patients who are symptomatic at baseline (average worst pain score \>0 and/or receiving opioids): A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits and an average worst pain score ≥4, and no decrease in average opioid use (≥1-point decrease in AQA score from a starting value of ≥2), or increase in opioid use (≥1-point increase, or ≥2-point increase if the starting value is 0) at 2 consecutive follow-up visits.

    Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)

  4. Number of Participants With Opiate Use

    An event for opiate use is defined as the first opiate use for cancer related pain.

    Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)

  5. Number of Participants With First Symptomatic Skeletal Related Event (SSRE)

    An SSRE event is defined as the first sympomatic skeletal-related event defined by * Use of radiation therapy to prevent or relieve skeletal symptoms. * Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral).

    Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)

  6. Number of Participants With Second Progression or Death (PFS2) Event

    An event for PFS2 is defined as the second progression on next-line anticancer therapy or death, whichever occurs earlier.

    Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)

  7. Brief Pain Inventory-Short Form (BPI-SF)

    The BPI-SF is a validated, 15-item domain-specific instrument designed to assess the severity of pain and the impact/interference of pain on daily functions. BPI-SF worst pain, pain severity and pain interference score changes can be a minimum of -10 and a maximum of 10. A negative change from baseline value indicates improvement.

    Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)

  8. Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P)

    Functional Assessment of Cancer Therapy-Prostate Cancer (FACT-P) total score and Functional Assessment of Cancer Therapy-General (FACT-G) total score. Total FACT-P score is the sum of Physical Well-being (PWB), Social Well-being (SWB), Emotional Well-being (EWB), Functional Well-being (FWB) and Prostate cancer subscale (PCS). FACT-P total score change from baseline values can be a minimum of -156 and a maximum of 156. A positive value indicates improvement. FACT-G total score is the sum of PWB, SWB, EWB and FWB. FACT-G Total score change from baseline values can be a minimum of -108 and a maximum of 108. A positive value indicates improvement.

    Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)

07

Results

Posted Jun 15, 2023

Participant flow

Participant flow — Overall Study
MilestoneOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
Started399397
Completed00
Not completed399397
Withdrew: Death168203
Withdrew: Other22
Withdrew: Failure to meet randomisation criteria11
Withdrew: Patient decision1410
Withdrew: Screen failure01
Withdrew: Patients ongoing study at data cut off210178
Withdrew: Lost to follow-up42

Outcome measures

PrimaryNumber of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment

An rPFS event is defined as progression determined by Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\] and/or Prostate Cancer Working Group 3 \[PCWG-3\] or death (by any cause in the absence of progression), regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy prior to progression. Per RECIST v1.1, progression is defined as the sum of TLs has a 20% and absolute ≥ 5mm increase from nadir, and/or unequivocal progression in any non target lesions, and/or any new lesion identified. Per PCWG3, progression on a bone scan is defined as 2 or more new lesions observed from the first visit after baseline compared to baseline, or from all other visits compared to first visit after baseline. A confirmatory scan is required.

Time frame:
Assessed from date of randomisation to data cut off (DCO1): 30Jul2021 (Approx. 2 years 9 months)
Reported as:
Count of participants · Participants
Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment
ParticipantsOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment168226
Statistical analysis
  • Olaparib 300 mg bd + Abiraterone 1000 mg qd vs Placebo bd + Abiraterone 1000 mg qd · Log Rank · p = <0.0001 (A multiple testing procedure is employed across primary (rPFS) and key secondary endpoints (OS) to strongly control overall type 1 error at 2.5% one-sided.) · Hazard ratio (hr): 0.66 · 95% CI 0.54 to 0.81HR and CI calculated using Cox Proportional Hazards model, where a HR \< 1 favours olaparib+abiraterone. Stratification factors are the same as those used in the stratified log-rank test.
SecondaryNumber of Participants With Overall Survival (OS) Event

An OS event is defined as death by any cause, regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy.

Time frame:
Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months). DCO3 is the final data cut-off for the OS analysis and therefore no further updates will be made.
Reported as:
Count of participants · Participants
Number of Participants With Overall Survival (OS) Event
ParticipantsOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
Number of Participants With Overall Survival (OS) Event176205
Statistical analysis
  • Olaparib 300 mg bd + Abiraterone 1000 mg qd vs Placebo bd + Abiraterone 1000 mg qd · Log Rank · p = 0.0544 (A multiple testing procedure is employed across primary (rPFS) and key secondary endpoints (OS) to strongly control overall type 1 error at 2.5% one-sided. Alpha spend for OS will not exceed 0.02135.) · Hazard ratio (hr): 0.81 · 95% CI 0.67 to 1.00HR and CI calculated using Cox Proportional Hazards model, where a HR \< 1 favours olaparib+abiraterone. Stratification factors are the same as those used in the stratified log-rank test.
SecondaryNumber of Participants With Time to First Subsequent Anticancer Therapy or Death (TFST) Event

A TFST (excluding radiotherapy) event is defined as the start of the first subsequent anticancer therapy after discontinuation of randomised treatment or death from any cause.

Time frame:
Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Reported as:
Count of participants · Participants
Number of Participants With Time to First Subsequent Anticancer Therapy or Death (TFST) Event
ParticipantsOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
Number of Participants With Time to First Subsequent Anticancer Therapy or Death (TFST) Event255285
Statistical analysis
  • Olaparib 300 mg bd + Abiraterone 1000 mg qd vs Placebo bd + Abiraterone 1000 mg qd · Log Rank · p = 0.0025 · Hazard ratio (hr): 0.76 · 95% CI 0.64 to 0.90HR and CI calculated using Cox Proportional Hazards model, where a HR \< 1 favours olaparib+abiraterone. Stratification factors are the same as those used in the stratified log-rank test.
SecondaryNumber of Participants With Time to Pain Progression (TTPP) Event

A TTPP event is defined as pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 (range 0-10, a higher score indicates worse pain) and opiate analgesic use (Analgesic quantification algorithm \[AQA\] score, range 0-7, a higher score indicates increased opioid use). For patients who are asymptomatic at baseline (average worst pain score of 0 and not taking opioids): A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits or initiation of opioid use; For patients who are symptomatic at baseline (average worst pain score \>0 and/or receiving opioids): A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits and an average worst pain score ≥4, and no decrease in average opioid use (≥1-point decrease in AQA score from a starting value of ≥2), or increase in opioid use (≥1-point increase, or ≥2-point increase if the starting value is 0) at 2 consecutive follow-up visits.

Time frame:
Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Reported as:
Count of participants · Participants
Number of Participants With Time to Pain Progression (TTPP) Event
ParticipantsOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
Number of Participants With Time to Pain Progression (TTPP) Event6860
Statistical analysis
  • Olaparib 300 mg bd + Abiraterone 1000 mg qd vs Placebo bd + Abiraterone 1000 mg qd · Log Rank · p = 0.7456 · Hazard ratio (hr): 1.06 · 95% CI 0.75 to 1.50HR and CI calculated using Cox Proportional Hazards model, where a HR \< 1 favours olaparib+abiraterone. Stratification factors are the same as those used in the stratified log-rank test.
SecondaryNumber of Participants With Opiate Use

An event for opiate use is defined as the first opiate use for cancer related pain.

Time frame:
Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Reported as:
Count of participants · Participants
Number of Participants With Opiate Use
ParticipantsOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
Number of Participants With Opiate Use5845
Statistical analysis
  • Olaparib 300 mg bd + Abiraterone 1000 mg qd vs Placebo bd + Abiraterone 1000 mg qd · Log Rank · p = 0.3099 · Hazard ratio (hr): 1.21 · 95% CI 0.82 to 1.79HR and CI calculated using Cox Proportional Hazards model, where a HR \< 1 favours olaparib+abiraterone. Stratification factors are the same as those used in the stratified log-rank test.
SecondaryNumber of Participants With First Symptomatic Skeletal Related Event (SSRE)

An SSRE event is defined as the first sympomatic skeletal-related event defined by * Use of radiation therapy to prevent or relieve skeletal symptoms. * Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral).

Time frame:
Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Reported as:
Count of participants · Participants
Number of Participants With First Symptomatic Skeletal Related Event (SSRE)
ParticipantsOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
Number of Participants With First Symptomatic Skeletal Related Event (SSRE)4651
Statistical analysis
  • Olaparib 300 mg bd + Abiraterone 1000 mg qd vs Placebo bd + Abiraterone 1000 mg qd · Log Rank · p = 0.3212 · Hazard ratio (hr): 0.82 · 95% CI 0.55 to 1.22HR and CI calculated using Cox Proportional Hazards model, where a HR \< 1 favours olaparib+abiraterone. Stratification factors are the same as those used in the stratified log-rank test.
SecondaryNumber of Participants With Second Progression or Death (PFS2) Event

An event for PFS2 is defined as the second progression on next-line anticancer therapy or death, whichever occurs earlier.

Time frame:
Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Reported as:
Count of participants · Participants
Number of Participants With Second Progression or Death (PFS2) Event
ParticipantsOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
Number of Participants With Second Progression or Death (PFS2) Event103126
Statistical analysis
  • Olaparib 300 mg bd + Abiraterone 1000 mg qd vs Placebo bd + Abiraterone 1000 mg qd · Log Rank · p = 0.0534 · Hazard ratio (hr): 0.76 · 95% CI 0.59 to 0.99HR and CI calculated using Cox Proportional Hazards model, where a HR \< 1 favours olaparib+abiraterone. Stratification factors are the same as those used in the stratified log-rank test.
SecondaryBrief Pain Inventory-Short Form (BPI-SF)

The BPI-SF is a validated, 15-item domain-specific instrument designed to assess the severity of pain and the impact/interference of pain on daily functions. BPI-SF worst pain, pain severity and pain interference score changes can be a minimum of -10 and a maximum of 10. A negative change from baseline value indicates improvement.

Time frame:
Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Reported as:
Least squares mean · Score
Brief Pain Inventory-Short Form (BPI-SF)
ScoreOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
Change from baseline in BPI-SF worst pain-0.09 ± 0.0930.03 ± 0.099
Change from baseline in BPI-SF pain severity score-0.08 ± 0.071-0.02 ± 0.076
Change from baseline in BPI-SF pain interference score0.01 ± 0.0740.13 ± 0.079
SecondaryFunctional Assessment of Cancer Therapy- Prostate Cancer (FACT-P)

Functional Assessment of Cancer Therapy-Prostate Cancer (FACT-P) total score and Functional Assessment of Cancer Therapy-General (FACT-G) total score. Total FACT-P score is the sum of Physical Well-being (PWB), Social Well-being (SWB), Emotional Well-being (EWB), Functional Well-being (FWB) and Prostate cancer subscale (PCS). FACT-P total score change from baseline values can be a minimum of -156 and a maximum of 156. A positive value indicates improvement. FACT-G total score is the sum of PWB, SWB, EWB and FWB. FACT-G Total score change from baseline values can be a minimum of -108 and a maximum of 108. A positive value indicates improvement.

Time frame:
Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Reported as:
Least squares mean · Score
Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P)
ScoreOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
Change from baseline in FACT-P Total-5.84 ± 1.031-5.30 ± 1.060
Change from baseline in FACT-G Total-5.06 ± 0.766-4.35 ± 0.787

Adverse events

Collected over Adverse events with an onset date, or worsen, on or after the date of first dose and up to and including 30 days following discontinuation of randomised treatment. Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib 300 mg bd + Abiraterone 1000 mg qd176/399 (44.1%)161/398 (40.5%)374/398 (94%)
Placebo bd + Abiraterone 1000 mg qd205/397 (51.6%)126/396 (31.8%)346/396 (87.4%)
Most frequent serious events
Showing 10 of 228
Most frequent serious events
EventOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
AnaemiaBlood and lymphatic system disorders23/3983/396
Pulmonary embolismRespiratory, thoracic and mediastinal disorders15/3983/396
Covid-19Infections and infestations15/39810/396
PneumoniaInfections and infestations11/3985/396
Urinary tract infectionInfections and infestations9/3983/396
Covid-19 pneumoniaInfections and infestations7/3983/396
UrosepsisInfections and infestations5/3982/396
Back painMusculoskeletal and connective tissue disorders5/3983/396
SyncopeNervous system disorders5/3982/396
Febrile neutropeniaBlood and lymphatic system disorders5/3982/396
Most frequent other events
Showing 10 of 44
Most frequent other events
EventOlaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qd
AnaemiaBlood and lymphatic system disorders184/39867/396
NauseaGastrointestinal disorders122/39856/396
FatigueGeneral disorders112/39881/396
Back painMusculoskeletal and connective tissue disorders82/39878/396
DiarrhoeaGastrointestinal disorders80/39842/396
ArthralgiaMusculoskeletal and connective tissue disorders58/39877/396
HypertensionVascular disorders61/39874/396
ConstipationGastrointestinal disorders74/39859/396
Decreased appetiteMetabolism and nutrition disorders66/39831/396
VomitingGastrointestinal disorders60/39836/396

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Olaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qdTotal
Mean68.5 ± 8.569.8 ± 7.969.1 ± 8.2
Age, Customized
Age, Customized(Participants)Olaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qdTotal
>=65269300569
<6513097227
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Olaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qdTotal
Male399397796
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Olaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qdTotal
HISPANIC OR LATINO6863131
NOT HISPANIC OR LATINO310305615
NOT REPORTED212950
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Olaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qdTotal
AMERICAN INDIAN OR ALASKA NATIVE101
ASIAN6672138
BLACK OR AFRICAN AMERICAN141125
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER202
NOT REPORTED223052
UNKNOWN12921
WHITE282275557
Region of Enrollment
Region of Enrollment(Participants)Olaparib 300 mg bd + Abiraterone 1000 mg qdPlacebo bd + Abiraterone 1000 mg qdTotal
USA403474
Turkey393372
Slovakia51318
Netherlands161228
Korea, Republic Of272956
Japan364177
Italy221840
United Kingdom272249
France142539
Spain192443
Germany141125
Czech Republic181331
Chile192544
Canada171633
Brazil5446100
Belgium415
Australia283462
08

Study locations

132 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Anchorage, Alaska 99503, United States
  • Research Site
    Tucson, Arizona 85704, United States
  • Research Site
    Tucson, Arizona 85741, United States
  • Research Site
    Clovis, California 93611, United States
  • Research Site
    Los Angeles, California 90027, United States
  • Research Site
    Los Angeles, California 90073, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Denver, Colorado 80211, United States
  • Research Site
    Lisle, Illinois 60532, United States
  • Research Site
    Jeffersonville, Indiana 47130, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    St Louis, Missouri 63106, United States
  • Research Site
    Bozeman, Montana 59715, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    Paramus, New Jersey 07652, United States
  • Research Site
    Brooklyn, New York 11220, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    Rochester, New York 14642, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Greenslopes, 4120, Australia
  • Research Site
    Herston, 4029, Australia
  • Research Site
    Kingswood, 2747, Australia
  • Research Site
    Kurralta Park, 5037, Australia
  • Research Site
    St Albans, 3021, Australia
  • Research Site
    Waratah, 2298, Australia
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Belo Horizonte, 30110-022, Brazil
  • Research Site
    Curitiba, 80810-050, Brazil
  • Research Site
    Fortaleza, 60336-232, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 22793-080, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01221-020, Brazil
  • Research Site
    São Paulo, 04266-010, Brazil
  • Research Site
    Calgary, Alberta T2V 1P9, Canada
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Research Site
    Montreal, Quebec H2X 3E4, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Santiago, 7500787, Chile
  • Research Site
    Santiago, 7520349, Chile
  • Research Site
    Temuco, 4781156, Chile
  • Research Site
    Viña del Mar, 2540488, Chile
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Prague, 120 00, Czechia
  • Research Site
    Prague, 140 59, Czechia
  • Research Site
    Prague, 150 06, Czechia
  • Research Site
    Angers, 49033, France
  • Research Site
    Besançon, 25030, France
  • Research Site
    Caen, 14076, France
  • Research Site
    Pierre-Bénite, 69495, France
  • Research Site
    Quimper, 29107, France
  • Research Site
    Vandœuvre-lès-Nancy, 54519, France
  • Research Site
    Bergisch Gladbach, 51465, Germany
  • Research Site
    Bremen, 28277, Germany
  • Research Site
    Cologne, 50968, Germany
  • Research Site
    Duisburg, 47169, Germany
  • Research Site
    Freiburg im Breisgau, 79106, Germany
  • Research Site
    Heinsberg, 52525, Germany
  • Research Site
    Mettmann, 40822, Germany
  • Research Site
    Nuremberg, 90419, Germany
  • Research Site
    Nürtingen, 72622, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Pavia, 27100, Italy
  • Research Site
    Bunkyō City, 113-8431, Japan
  • Research Site
    Hirakata-shi, 573-1191, Japan
  • Research Site
    Kanazawa, 920-8641, Japan
  • Research Site
    Kashihara-shi, 634-8522, Japan
  • Research Site
    Kawagoe-shi, 350-8550, Japan
  • Research Site
    Kita-gun, 761-0793, Japan
  • Research Site
    Kyoto, 606-8507, Japan
  • Research Site
    Maebashi, 371-8811, Japan
  • Research Site
    Miyazaki, 889-1692, Japan
  • Research Site
    Nagoya, 466-8560, Japan
  • Research Site
    Osaka, 541-8567, Japan
  • Research Site
    Osaka, 545-8586, Japan
  • Research Site
    Osakasayama-shi, 589-8511, Japan
  • Research Site
    Sagamihara-shi, 252-0375, Japan
  • Research Site
    Sakura-shi, 285-8741, Japan
  • Research Site
    Shinjuku-ku, 160-8582, Japan

Showing the first 100 of 132 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Armstrong AJ, Saad F, Oya M, Shore N, Procopio G, Arslan C, Mehra N, Brown E, Joung JY, Sugimoto M, Ozguroglu M, Gedye C, Sartor O, Poehlein C, Qiu P, Liu YZ, Li X, Harrington EA, McGuinness D, Kang J, Barnicle A, Clarke N. Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial. JCO Precis Oncol. 2026 May;10(5):e2501109. doi: 10.1200/PO-25-01109. Epub 2026 May 11. PubMed 42114035 ↗
  • Armstrong AJ, Saad F, Oya M, Vianna K, Ozguroglu M, Gedye C, Buchschacher GL Jr, Lee JY, Emmenegger U, Navratil J, Virizuela JA, Salazar A, Maillet D, Uemura H, Hosius C, McGuinness D, Degboe A, Clarke N. Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study. Eur Urol Oncol. 2026 Feb;9(1):80-92. doi: 10.1016/j.euo.2025.09.010. Epub 2025 Nov 17. PubMed 41253648 ↗
  • Oya M, Joung JY, Lee JY, Sugimoto M, Choi YD, Hong JH, Uemura H, Nishimura K, Tsumura H, Kawakami S, Hirayama Y, Kwon TG, Kwak C, Suzuki H, Fujita T, Nii M, McGuinness D, Dujka M, Poehlein C, Saad F, Clarke N. Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset Analysis. Cancer Sci. 2025 Jun;116(6):1638-1647. doi: 10.1111/cas.16459. Epub 2025 Mar 18. PubMed 40099663 ↗
  • Heiss BL, Chang E, Gao X, Truong T, Brave MH, Bloomquist E, Shah A, Hamed S, Kraft J, Chiu HJ, Ricks TK, Tilley A, Pierce WF, Tang L, Abukhdeir A, Kalavar S, Philip R, Tang S, Pazdur R, Amiri-Kordestani L, Kluetz PG, Suzman DL. US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2024 May 20;42(15):1851-1860. doi: 10.1200/JCO.23.02182. Epub 2024 Mar 7. PubMed 38452327 ↗
  • Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, Procopio G, de Menezes J, Girotto G, Arslan C, Mehra N, Parnis F, Brown E, Schlurmann F, Joung JY, Sugimoto M, Virizuela JA, Emmenegger U, Navratil J, Buchschacher GL, Poehlein C, Harrington EA, Desai C, Kang J, Saad F. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2022 Sep;1(9):EVIDoa2200043. doi: 10.1056/EVIDoa2200043. Epub 2022 Jun 3. PubMed 38319800 ↗
  • Fallah J, Xu J, Weinstock C, Brave MH, Bloomquist E, Fiero MH, Schaefer T, Pathak A, Abukhdeir A, Bhatnagar V, Chiu HJ, Ricks T, John C, Hamed S, Lee C, Pierce WF, Kalavar S, Philip R, Tang S, Amiri-Kordestani L, Pazdur R, Kluetz PG, Suzman D. FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2024 Feb 10;42(5):605-613. doi: 10.1200/JCO.23.01868. Epub 2023 Dec 21. PubMed 38127780 ↗
  • Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlurmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. PubMed 37714168 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jul 2021, 32 months.

Results were first posted in Jun 2023, 1 year 10 months after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 32 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2018
First posted
Nov 7, 2018
StartActual
Oct 31, 2018
Primary completionActual
Jul 30, 2021
CompletionEst.
Feb 5, 2027
Results first posted
Jun 15, 2023
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03732820
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 7, 2018
Start date
Oct 31, 2018
Primary completion
Jul 30, 2021
Completion
Feb 5, 2027 (estimated)
Results posted
Jun 15, 2023
Last update
Aug 18, 2026

Study contacts

Fred Saad, MD
principal investigator · University of Montreal Hospital Center
Noel Clarke, M.D.
principal investigator · Christie Hospital Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion